BridgeMD
Benefit of transplantation after Complete Response In Patients with T-cell lymphoma
EU CTIS ID: 2022-501710-62-02
What this study is testing
The principal objective of the study is to assess if autologous stem cell transplantation (ASCT) is associated with a significant prolongation of progression-free survival (PFS) for patient with peripheral T-cell lymphoma (PTCL) reaching a complete response (CR) according to the response criteria for lymphoma – Lugano 2014 after 6 cycles of induction chemotherapy (PET-CT-based response for FDG-avid lymphomas or CT-based response if not).
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient ≥ 18 years and < 70 years of age at the time of signing the informed consent form (ICF)
- Patient who understood and voluntarily signed and dated an informed consent prior to any study-specific assessments/procedures being conducted
- Able to adhere to the study visit schedule and other protocol requirements
- Patient covered by any social security system
- Patient who understands and speaks one of the country official languages
- Males with partners of childbearing potential must agree to use effective birth control methods during the study and: for 6 months after last treatments administration (i.e. drugs administered according to the standard of care in the context of protocol)
You likely can't join if
- Known central nervous system or meningeal involvement by lymphoma
- Pregnant, planning to become pregnant or lactating WOCBP
- Any significant medical conditions, laboratory abnormality or psychiatric illness likely to interfere with the participation in this clinical study (according to the investigator’s decision)
- Person deprived of his/her liberty by a judicial or administrative decision
- Person hospitalized without consent
- Adult person under legal protection
See the full eligibility criteria
Who can join
- Patient ≥ 18 years and < 70 years of age at the time of signing the informed consent form (ICF)
- Patient who understood and voluntarily signed and dated an informed consent prior to any study-specific assessments/procedures being conducted
- Able to adhere to the study visit schedule and other protocol requirements
- Patient covered by any social security system
- Patient who understands and speaks one of the country official languages
- Males with partners of childbearing potential must agree to use effective birth control methods during the study and: for 6 months after last treatments administration (i.e. drugs administered according to the standard of care in the context of protocol)
- Females of childbearing potential must agree to use effective birth control methods for at least 28 days before starting treatment; while participating in the study; during treatment interruptions and for 12 months after last treatments administration (i.e. drugs administered according to the standard of care in the context of protocol)
- Patient fit enough to receive autologous stem cell transplant as a consolidation strategy as assessed by the local investigator
- Hemoglobin level > 8g/dL (transfusion allowed); Neutrophil count >0.5 G/L; Platelets count > 50 G/L (transfusion allowed)
- Patient with histologically proven “nodal-type peripheral T-cell lymphoma (PTCL)” (latest WHO classification), not previously treated; as defined by the WHO classification, the following subtypes may be included, o PTCL, not otherwise specified o Follicular helper T-cell lymphomas: Angioimmunoblastic T-cell lymphoma and nodal PTCL with TFH phenotype and follicular T-cell lymphoma o Anaplastic large cell lymphoma, ALK-negative
- Ann Arbor staging (I-IV) except stage I with normal LDH and PS<2 (i.e. stage I aaIPI 0)
- Participant with a measurable disease by the Lugano criteria (i.e., longest diameter of a nodal site > 1.5 cm and/or longest diameter of an extranodal site > 1.0 cm and/or a hypermetabolic lesion)
- FFPE Diagnostic tissue block should be available for central pathology review and ancillary molecular analyses
- Participant with Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
- Estimated minimum life expectancy of 3 months
What rules you out
- Known central nervous system or meningeal involvement by lymphoma
- Pregnant, planning to become pregnant or lactating WOCBP
- Any significant medical conditions, laboratory abnormality or psychiatric illness likely to interfere with the participation in this clinical study (according to the investigator’s decision)
- Person deprived of his/her liberty by a judicial or administrative decision
- Person hospitalized without consent
- Adult person under legal protection
- Impaired renal function (calculated MDRD or Cockcroft-Gault Creatinine Clearance < 30 ml/min) or impaired liver function tests (serum total bilirubin level > 2.0 mg/dl [34 µmol/L] (except in case of Gilbert’s Syndrome, or documented liver or pancreatic involvement by lymphoma), serum transaminases (AST or ALT) > 3 upper normal limit unless they are related to the lymphoma.
- The following types of T-cell lymphomas: o Adult T-cell lymphoma/leukemia (HTLV-1 related T-cell lymphoma) o Extranodal T-cell/NK-cell lymphoma, nasal type o Anaplastic large cell lymphoma, ALK-positive type o Cutaneous T cell lymphoma (mycosis fungoides, Sézary syndrome) o Primary cutaneous CD30+ T-cell lymphoproliferative disorder o Primary cutaneous anaplastic T-cell lymphoma o Enteropathy-associated T-cell lymphoma o Hepatosplenic T-cell lymphoma o Subcutaneous panniculitis-like T-cell lymphoma o Primary cutaneous gamma-delta T-cell lymphoma o Primary cutaneous CD8+ aggressive epidermotropic lymphoma o Primary cutaneous CD4+ small/medium T-cell lymphoma
- Active malignancy other than the one treated in this research. Prior history of malignancies unless the patient has been free of the disease for ≥ 2 years. However, patients with the following history are allowed: a. Basal or squamous cell carcinoma of the skin b. Carcinoma in situ of the cervix c. Carcinoma in situ of the breast d. Incidental histologic finding of prostate cancer (T1a or T1b) using the tumor, nodes, metastasis clinical staging system
- Vaccinated with live, attenuated vaccines within 6 months of enrollment
- Use of any standard or experimental anti-cancer drug therapy before the start of treatment except COP (cycloposphamide, vincristine, prednisone) in case of emergency (or high risk of tumor lysis syndrome) or etoposide for a maximum of 3 doses (at a maximum dose of 150mg/m2) for HLH (Hemophagocytic Lymphohistiocytosis).
- A corticosteroids therapy > 1mg/kg lasting more than 14 days prior to Cycle 1 Day 1
- Positive serology for Human Immunodeficiency Virus (HIV) and Human T-Lymphotrophic Virus (HTLV1)
- Active Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infections defined as: HBV : HBs Ag positive / HBs Ag negative, anti-HBs antibody positive and anti-HBc antibody positive with detectable viral DNA - HCV : Anti-VHC antibody positive with detectable viral RNA
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.